痹懈分清饮治疗慢性前列腺炎的系统评价和 Meta 分析。
Bixie Fenqing decoction in the treatment of chronic prostatitis: A systematic review and meta-analysis.
机构信息
First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, China.
Department of Andrology, Reproductive Medicine, Yunnan Provincial Hospital of Chinese Medicine, The First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China.
出版信息
Medicine (Baltimore). 2024 Sep 13;103(37):e39558. doi: 10.1097/MD.0000000000039558.
BACKGROUND
Traditional Chinese medicine (TCM) posits that chronic prostatitis is associated with the accumulation of damp-heat pathogenic factors in the lower jiao. The Bixie Fenqing decoction (BFD) eliminates damp-heat pathogenic factors in the body, thereby alleviating inflammation and improving symptoms.
METHODS
Databases such as CNKI, WanFang, VIP, CBM, ClinicalKey, PubMed, Embase, and the Cochrane Library were searched. The search time ranged from the establishment of the database until March 30, 2024. RCTs that used BFD for chronic prostatitis were screened. The methodological quality of the studies was evaluated using the Cochrane Scoring System. Meta-analysis of outcome indicators was performed using RevMan 5.4 software, and Egger analysis of publication bias for the primary outcome indicators was conducted using Stata 16 software.
RESULTS
This analysis included 1104 patients. Meta-analysis showed that BFD significantly improved clinical efficacy in patients with chronic prostatitis, with a total effective rate (RR = 1.20, 95% CI: 1.13 to 1.26, P < .00001) and cure rate (RR = 1.52, 95% CI: 1.24 to 1.86, P < .00001). It significantly reduced the NIH-CPSI (National Institutes of Health-Chronic Prostatitis Symptom Index) scores, levels of inflammatory factors, white blood cell counts, and TCM syndrome scores in patients with chronic prostatitis. Specifically, the NIH-CPSI total scores (MD = -4.41, 95% CI: -5.27 to -3.55, P < .00001), NIH-CPSI pain scores (MD = -2.08, 95% CI: -2.93 to -1.23, P < .00001), NIH-CPSI urinary symptom scores (MD = -1.13, 95% CI: -1.69 to -0.57, P < .0001), NIH-CPSI quality of life scores (MD = -1.25, 95% CI: -1.76 to -0.75, P < .00001), levels of inflammatory factors TNF-α (MD = -11.18, 95% CI: -13.84 to -8.53, P < .00001) and IL-10 (MD = -20.60, 95% CI: -26.82 to -14.37, P < .00001) in prostatic fluid, white blood cell counts in prostatic fluid (MD = -2.91, 95% CI: -5.46 to -0.36, P = .03), and TCM syndrome scores (MD = -7.01, 95% CI: -8.13 to -5.90, P < .00001) were all significantly improved.
CONCLUSION
BFD has a definite effect on the treatment of chronic prostatitis.
背景
中医认为慢性前列腺炎与下焦湿热病邪的积聚有关。萆薢分清饮可祛除体内湿热病邪，从而缓解炎症，改善症状。
方法
检索中国知网、万方、维普、中国生物医学文献数据库、ClinicalKey、PubMed、Embase 和 Cochrane 图书馆等数据库，检索时间从数据库建立到 2024 年 3 月 30 日。筛选出使用萆薢分清饮治疗慢性前列腺炎的随机对照试验。使用 Cochrane 评分系统评价研究的方法学质量。使用 RevMan 5.4 软件对结局指标进行荟萃分析，使用 Stata 16 软件对主要结局指标进行发表偏倚的 Egger 分析。
结果
本分析纳入了 1104 例患者。荟萃分析显示，萆薢分清饮可显著提高慢性前列腺炎患者的临床疗效，总有效率（RR=1.20，95%CI：1.131.26，P<0.00001）和治愈率（RR=1.52，95%CI：1.241.86，P<0.00001）均有显著提高。它还显著降低了慢性前列腺炎患者的 NIH-CPSI（美国国立卫生研究院-慢性前列腺炎症状指数）评分、炎症因子水平、白细胞计数和中医证候评分。具体而言，NIH-CPSI 总分（MD=-4.41，95%CI：-5.27-3.55，P<0.00001）、NIH-CPSI 疼痛评分（MD=-2.08，95%CI：-2.93-1.23，P<0.00001）、NIH-CPSI 排尿症状评分（MD=-1.13，95%CI：-1.69-0.57，P<0.0001）、NIH-CPSI 生活质量评分（MD=-1.25，95%CI：-1.76-0.75，P<0.00001）、前列腺液中炎症因子 TNF-α（MD=-11.18，95%CI：-13.84-8.53，P<0.00001）和 IL-10（MD=-20.60，95%CI：-26.82-14.37，P<0.00001）水平、前列腺液中的白细胞计数（MD=-2.91，95%CI：-5.46-0.36，P=0.03）和中医证候评分（MD=-7.01，95%CI：-8.13-5.90，P<0.00001）均有显著改善。
结论
萆薢分清饮治疗慢性前列腺炎的疗效确切。
Zotero 插件